[
    [
        {
            "time": "2018-03-15",
            "original_text": "Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?",
            "features": {
                "keywords": [
                    "VanEck",
                    "Vectors",
                    "Pharmaceutical",
                    "ETF",
                    "PPH"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Lilly",
                    "Tanezumab",
                    "Phase 3",
                    "Osteoarthritis",
                    "Pain"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Lilly",
                    "Tanezumab",
                    "Phase 3",
                    "OA",
                    "Pain"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-02-05",
            "original_text": "Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?",
            "features": {
                "keywords": [
                    "Dr. Reddy's",
                    "RDY",
                    "Q3",
                    "Earnings"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]